Amerise Biosciences Limited - pharma in Ahmedabad, Gujarat, India. FY 2026 financials & compliance.
CIN L29199GJ1984PLC007195 Incorporated 27 August 1984 ROC Ahmedabad HQ Ahmedabad, Gujarat, India
Active Listed - BSE: 531681 Public Limited Company pharma
Market Cap
₹5.48 Cr
AMERISE · BSE
Share Price
₹0.84
+1.20% today
Revenue
₹0.26 Cr
FY 2025-26 · +36.8% YoY
EBITDA
₹0.03 Cr
Margin 11.5%
Net Profit
₹0.03 Cr
FY 2025-26 · +200.0% YoY
Authorised capital
₹7.5 Cr
Registered with MCA
Paid-up capital
₹6.61 Cr
Issued & subscribed
Open charges
₹38.39 Lakh
Secured borrowings

About Amerise Biosciences Limited

Data last updated:

Amerise Biosciences Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 27 August 1984 and has been in existence for over 42 years.

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L29199GJ1984PLC007195. It is a listed company as per MCA records. Its shares are listed on BSE: 531681.

The company has an authorised share capital of ₹7.5 Cr and a paid-up capital of ₹6.61 Cr. It was formerly known as Amradeep Industries Limited. It is led by directors including Albert Hines (Whole-Time Director) and Manisha Patel Maneklal.

Its last annual general meeting (AGM) was held on 23 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 24 Laxmi Chambers Navjeevan Press Road Opp. Old Gujarat High Court, Ahmedabad, Gujarat, India – 380014.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹26 Lakh, a growth of 36.8% compared to the previous year. For the same year it recorded a net profit of ₹3 Lakh (net margin 11.5%) and EBITDA of ₹3 Lakh (EBITDA margin 11.5%). The net worth stands at ₹5.4 Cr (up 0.4% YoY). Total assets are valued at ₹5.4 Cr (up 0.4% YoY).

As per MCA filings, the company has open charges of ₹38.39 Lakh on record. The company has 28 deals on record (28 market trades); the latest was in July 2026.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website amradeepindustries.in.

Company details

CIN L29199GJ1984PLC007195
Registration Number 007195
Incorporation Date 27 August 1984
ROC Ahmedabad
Listing Status Listed - Listed on BSE (531681)
Company Status Active
Compliance Status Active Compliant

CIN history

Amerise Biosciences has one previous CIN (Corporate Identification Number): U29199GJ1984PLC007195. The current CIN is L29199GJ1984PLC007195, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L29199GJ1984PLC007195Current
U29199GJ1984PLC007195Previous

Contact details

Amerise Biosciences Limited's registered office is in Ahmedabad, Gujarat. Its website is amradeepindustries.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Registered Address
    24 Laxmi Chambers Navjeevan Press Road Opp. Old Gujarat High Court, Ahmedabad, Gujarat, India – 380014
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Amerise Biosciences Limited, buy the company report.

Comprehensive company report
Amerise Biosciences Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Financials of Amerise Biosciences Limited

FY 2025-26 filings available

Amerise Biosciences Limited reported revenue of ₹26 Lakh (up 36.8% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹0.26 Cr
+36.8% YoY
EBITDA
₹0.03 Cr
+200.0% YoY
Profit After Tax
₹0.03 Cr
+200.0% YoY
Net Worth
₹5.40 Cr
+0.4% YoY
Total Assets
₹5.40 Cr
+0.4% YoY
Total Debt
Nil

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue0.260.190.040.019.580.000.00
Revenue growth+36.8%+375.0%+300.0%-99.9%---
EBITDA0.030.01(0.14)(0.12)0.56(0.17)(0.15)
EBITDA margin+11.5%+5.3%-350.0%-1200.0%+5.9%--
Profit before tax0.030.01(0.14)(0.12)0.56(0.34)(0.15)
Net profit0.030.01(0.14)(0.12)0.56(0.34)(0.15)
Net profit margin+11.5%+5.3%-350.0%-1200.0%+5.9%--
EPS (₹)0.000.00(0.02)(0.02)0.08(0.05)(0.02)
Balance sheet
Total assets5.405.385.375.615.725.095.43
Net worth5.405.385.385.525.645.095.43
Total debt0.000.000.000.090.080.000.00
Cash & bank0.590.020.020.010.010.020.03
Net working capital(1.42)(3.06)0.00(0.03)(0.04)(0.52)(0.57)
Cash flow
Cash from operations(1.06)3.07(0.17)(0.13)0.06(0.39)4.89
Cash from investing1.63(3.07)0.270.13(0.15)0.39(4.89)
Cash from financing0.000.00(0.09)0.010.080.000.00
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.000.080.040.070.060.190.000.00
Revenue growth (YoY)-100.0%-57.9%------
Other income0.000.000.000.000.000.000.000.00
Total expenses0.080.020.040.110.070.080.020.03
EBITDA(0.08)0.060.00(0.04)(0.01)0.11(0.02)(0.03)
Depreciation0.000.000.000.000.000.000.000.00
Interest0.000.000.000.000.000.000.000.00
Profit before tax(0.08)0.060.00(0.04)(0.01)0.11(0.02)(0.03)
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 18 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue0.000.080.040.070.060.190.000.00
Revenue growth (YoY)-100.0%-57.9%------
Other income0.000.000.000.000.000.000.000.00
Total expenses0.080.020.040.110.070.080.020.03
EBITDA(0.08)0.060.00(0.04)(0.01)0.11(0.02)(0.03)
Depreciation0.000.000.000.000.000.000.000.00
Interest0.000.000.000.000.000.000.000.00
Profit before tax(0.08)0.060.00(0.04)(0.01)0.11(0.02)(0.03)
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue0.260.190.040.019.580.000.00
Revenue growth+36.8%+375.0%+300.0%-99.9%---
Other income0.000.000.000.000.00(0.17)0.00
Total expenses0.230.180.180.139.020.170.15
Employee cost0.000.100.070.020.050.040.04
EBITDA0.030.01(0.14)(0.12)0.56(0.17)(0.15)
EBITDA margin+11.5%+5.3%-350.0%-1200.0%+5.9%--
Depreciation0.000.000.000.000.000.000.00
Interest0.000.000.000.000.000.000.00
Profit before tax0.030.01(0.14)(0.12)0.56(0.34)(0.15)
Tax0.000.000.000.000.000.000.00
Net profit0.030.01(0.14)(0.12)0.56(0.34)(0.15)
Net profit margin+11.5%+5.3%-350.0%-1200.0%+5.9%--
EPS (₹)0.000.00(0.02)(0.02)0.08(0.05)(0.02)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital6.616.616.616.616.616.616.61
Reserves & surplus(1.21)(1.23)(1.23)(1.09)(0.97)(1.52)(1.18)
Shareholders' funds (net worth)5.405.385.385.525.645.095.43
Secured loans0.000.000.000.000.000.000.00
Unsecured loans0.000.000.000.090.080.000.00
Total debt0.000.000.000.090.080.000.00
Total liabilities5.405.385.375.615.725.095.43
Assets
Gross block0.000.000.000.000.000.000.00
Net block0.000.000.000.000.000.000.00
Capital work in progress0.000.000.000.000.000.000.00
Investments3.772.382.274.574.693.045.37
Inventories0.000.000.000.000.000.000.00
Sundry debtors0.000.000.000.006.220.000.00
Cash & bank balances0.590.020.020.010.010.020.03
Loans & advances0.020.000.000.000.000.000.00
Total current assets0.610.020.020.016.230.020.03
Total current liabilities2.033.080.020.046.270.540.60
Net working capital(1.42)(3.06)0.00(0.03)(0.04)(0.52)(0.57)
Total assets5.405.385.375.615.725.095.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.020.020.010.010.020.030.02
Net cash from operating activities(1.06)3.07(0.17)(0.13)0.06(0.39)4.89
Net cash from investing activities1.63(3.07)0.270.13(0.15)0.39(4.89)
Net cash from financing activities0.000.00(0.09)0.010.080.000.00
Net change in cash0.570.000.010.00(0.01)(0.01)0.01
Closing cash0.590.020.020.010.010.020.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+36.8%+375.0%+300.0%-99.9%---
EBITDA growth+200.0%+107.1%-16.7%-121.4%+429.4%-13.3%-
PBT growth+200.0%+9998.0%-16.7%-+9998.0%-126.7%-
Net income growth+200.0%+107.1%-16.7%-121.4%+264.7%-126.7%-
Revenue CAGR (3Y)+196.3%-72.9%--+101.0%--
EBITDA CAGR (3Y)--73.9%-6.3%-7.2%+282.6%+104.1%-45.8%
Profitability & leverage
Net income margin+11.5%+5.3%-350.0%-1200.0%+5.9%--
Return on capital employed-+0.2%0.0%0.0%+9.3%0.0%0.0%
Return on net worth-+0.2%0.0%0.0%+9.3%0.0%0.0%
Debt / equity-0.000.010.020.010.000.00
Long-term debt / equity-0.000.010.020.010.000.00
Interest cover0.000.000.000.000.000.000.00
Efficiency & per share
Fixed asset turnover-0.000.000.000.000.000.00
Inventory turnover-0.000.000.000.000.000.00
Debtors turnover-0.000.000.003.080.000.00
EPS (₹)0.000.00(0.02)(0.02)0.08(0.05)(0.02)
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.000.810.810.840.850.770.82

To see the full year-wise statements and ratios of Amerise Biosciences Limited, buy the company report.

Board of directors of Amerise Biosciences Limited

Amerise Biosciences has 3 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Manisha Patel ManeklalDirector24 Jun 20197 Years 4 MonthsCurrent
Albert HinesWhole-Time Director02 Feb 20260 Years 9 MonthsCurrent
Kelash BunkarDirector03 Feb 20251 Years 9 MonthsCurrent

Auditor

Amerise Biosciences Limited is audited by BIPIN & CO for the financial year 2023.

Auditor firmFinancial yearFirm registration number
BIPIN & COFY 2023101509W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 0.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 100.00%.

Retail & Others: 100.00%
Sep 2026
QUARTER
100.00% Retail & Others
Public holding - history
Now 100.00% · Sep 2026High 100.00% · Dec 2025Low 100.00% · Dec 2025
99%99.3%99.5%99.8%100%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 100.00%Mar 2026: 100.00%Jun 2026: 100.00%Sep 2026: 100.00%100.00%100.00%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters0.00%0.00%0.00%0.00%
Public100.00%100.00%100.00%100.00%

Charges & borrowings

Open charges
₹38.39 Lakh
Satisfied charges
None
Breakdown by lending institutions
Gujarat State Financial Corporation₹0.29 Cr
Bank of Baroda₹0.09 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
17 Mar 198790097221Bank of Baroda₹9 LakhOpen
20 Aug 198590097165Gujarat State Financial Corporation₹29.39 LakhOpen

To see the full charge records of Amerise Biosciences Limited, buy the company report.

Total charge records: 2 View all charges

Deals & funding

Amerise Biosciences Limited has 28 deals on record (28 market trades); the latest was in July 2026.

Total deals
28
Market trades
28

Deals on record (5 of 28)

WhenDealAmountParties
Jul 2026Market trade₹4 LakhSeller: an individual
Apr 2026Market trade₹2.8 LakhBuyer: Snehjeev Ventures Private Limited
Seller: an individual
Feb 2026Market trade₹3.9 LakhBuyer: an individual
Seller: an individual
Oct 2025Market trade₹2.8 LakhSeller: an individual
Feb 2010Market trade₹13.46 CrBuyer: Parvati Minerals Private Limited
Seller: Anukaran Commercial Enterprises Limited

To see the full deal history of Amerise Biosciences Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Amerise Biosciences Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

No GST registration is on our record for Amerise Biosciences Limited; the GSTIN and return-filing check is in the company report Buy the company report.

Recent activity

Amerise Biosciences Limited has 23 board changes on record since 2008: 3 appointments and 20 cessations. The latest: Albert Hines was appointed as Whole-Time Director on 02 Feb 2026.

Filing
Amerise Biosciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Appointed
Albert Hines was appointed as Whole-Time Director.
Ceased
Dineshkumar Tribhovanbhai Rathod ceased to be Whole-Time Director.
AGM
Amerise Biosciences Limited last Annual general meeting of members was held on 23 Sep 2025 as per latest MCA records.
Appointed
Kelash Bunkar was appointed as Director.
Ceased
Niraj Vaghela ceased to be Additional Director.
Ceased
Bhavin Padaliya ceased to be Director.
Ceased
Darshan Ashwinkumar Bhatt ceased to be Additional Director.
Appointed
Manisha Patel Maneklal was appointed as Director.
Ceased
Deenaben Mahendrabhai Ganatra ceased to be Director.
Ceased
Sagarkumar Kishorbhai Gajera ceased to be Director.
Ceased
Vineet Deorari ceased to be Director.

18 earlier events are in the company report.

Frequently asked questions

Amerise Biosciences is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 27 August 1984 (42+ years old) and is registered under CIN L29199GJ1984PLC007195. Listed on BSE: 531681.

Amerise Biosciences reported revenue of ₹26 Lakh for FY 2025-26 (up 36.8% YoY) based on standalone financials.

Amerise Biosciences has 3 current directors:

The latest financial statements of Amerise Biosciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 23 September 2025. Year-wise statements from 2015 are in the company report.

The CIN (Corporate Identification Number) of Amerise Biosciences is L29199GJ1984PLC007195. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Amerise Biosciences is a listed company as per MCA records. Its shares are listed on BSE (code: 531681).

Amerise Biosciences was incorporated on 27 August 1984, making it 42+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Amerise Biosciences has 28 deals on record (28 market trades); the latest was in July 2026.

Albert Hines was appointed as Whole-Time Director on 02 Feb 2026. Dineshkumar Tribhovanbhai Rathod ceased to be Whole-Time Director on 02 Feb 2026. Kelash Bunkar was appointed as Director on 03 Feb 2025. Amerise Biosciences has 23 board changes on record in total.

Amerise Biosciences can be reached through the website amradeepindustries.in. Its registered office is in Ahmedabad, Gujarat, India.